Cargando…
Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma
Immune checkpoint inhibitors enrich the therapeutic landscape in oesophago-gastric carcinoma. With regard to oesophageal squamous cell carcinoma (ESCC), the selective PD-1 (programmed cell death receptor 1)-inhibitor nivolumab improves disease-free survival in the adjuvant therapy setting (CHECKMATE...
Autores principales: | Högner, Anica, Thuss-Patience, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918118/ https://www.ncbi.nlm.nih.gov/pubmed/33673374 http://dx.doi.org/10.3390/ph14020151 |
Ejemplares similares
-
Immunotherapy in Gastric Cancer
por: Högner, Anica, et al.
Publicado: (2022) -
Optimising Multimodality Treatment of Resectable Oesophago-Gastric Adenocarcinoma
por: Suwaidan, Ali Abdulnabi, et al.
Publicado: (2022) -
Prognostic Relevance of Weight and Weight Loss during Multimodal Therapy for Oesophagogastric Tumours
por: Lorusso, Alessandro, et al.
Publicado: (2022) -
The pattern of recurrence of adenocarcinoma of the oesophago-gastric junction
por: Wayman, J, et al.
Publicado: (2002) -
Neoadjuvant chemotherapy for carcinoma of the oesophagus and oesophago-gastric junction: a six-year experience
por: Halliday, Brian P, et al.
Publicado: (2007)